Technical Analysis for IMUX - Immunic, Inc.

Grade Last Price % Change Price Change
grade B 18.04 -7.15% -1.39
IMUX closed down 7.15 percent on Wednesday, August 5, 2020, on 5.72 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical IMUX trend table...

Date Alert Name Type % Chg
Volume Surge Other 0.00%
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
Slingshot Bullish Bullish Swing Setup -7.15%
Calm After Storm Range Contraction -7.15%
Upper Bollinger Band Walk Strength -7.15%
Multiple of Ten Bearish Other -7.15%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Immunic, Inc. (Nasdaq:IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn's disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.
Medicine Biopharmaceutical Medical Specialties Clinical Medicine Immunotherapy Autoimmune Diseases Multiple Sclerosis Psoriasis Ulcerative Colitis Abdominal Pain Crohn's Disease Primary Sclerosing Cholangitis Relapsing Remitting Multiple Sclerosis Mayo Clinic

Is IMUX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.39
52 Week Low 4.19
Average Volume 494,523
200-Day Moving Average 9.58
50-Day Moving Average 13.87
20-Day Moving Average 15.57
10-Day Moving Average 17.52
Average True Range 1.69
ADX 39.27
+DI 41.99
-DI 17.71
Chandelier Exit (Long, 3 ATRs ) 18.31
Chandelier Exit (Short, 3 ATRs ) 16.83
Upper Bollinger Band 20.90
Lower Bollinger Band 10.23
Percent B (%b) 0.73
BandWidth 68.57
MACD Line 1.61
MACD Signal Line 1.28
MACD Histogram 0.3357
Fundamentals Value
Market Cap 761.42 Million
Num Shares 42.2 Million
EPS -1.35
Price-to-Earnings (P/E) Ratio -13.36
Price-to-Sales 0.00
Price-to-Book 3.02
PEG Ratio -0.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.26
Resistance 3 (R3) 19.24 18.83 19.05
Resistance 2 (R2) 18.83 18.52 18.83 18.98
Resistance 1 (R1) 18.43 18.33 18.63 18.45 18.92
Pivot Point 18.02 18.02 18.12 18.02 18.02
Support 1 (S1) 17.62 17.71 17.82 17.64 17.16
Support 2 (S2) 17.21 17.52 17.21 17.10
Support 3 (S3) 16.81 17.21 17.03
Support 4 (S4) 16.83